Rockland Technimed Ltd and Fresenius-Kabi Product Partnering, , Austria have executed a partnership agreement today for manufacturing development of Oxy-17^® as a ready to use injectable, imaging media, for invivo, realtime metabolic imaging using an unaltered MRI scanner.

Fresenius-Kabi will be RTL's manufacturing partner for worldwide supply of Oxy-17^® in the required packaging, to RTLs distribution and marketing partners in various markets.

For any information please contact us atTel: +1-845-426-3406 , Fax +1-845-436-1109Email: staff@technimed.com

Regulatory News Focus:

New York Times August 1, 2010

The Radiation Boom

After Stroke Scans, Patients Face Serious Health Risks

By WALT BOGDANICH

Published: July 31, 2010

Link to the article

US Food and Drug Administration, Dec 22, 2006:Public Health Advisory

Update on Magnetic Resonance Imaging (MRI) Contrast Agents Containing Gadolinium and Nephrogenic Fibrosing Dermopathy.

Link to US FDA Public Advisory

Health Canada Advises Canadians of Safety Issues Related to Gadolinium-Containing Contrast Agents Used in Magnetic Resonance Imaging (MRI)

Link to Canada Health Advisory

UK.MHRA-Medicines and Healthcare products Regulatory Agency -

Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents

Public Assessment Report

Questions and Answers